Horizon Pharma Sells European Subsidiary for $70+ Million

San Diego – June 1, 2017 – Cooley advised Horizon Pharma on its agreement to sell a European subsidiary that owns the marketing rights to two commercial products in Europe, the Middle East and Africa to Chiesi Farmaceutici for an upfront payment of $70 million and potential for future milestone payments.

The commercial products are PROCYSBI (cysteamine bitartrate) delayed-release capsules and QUINSAIR (levofloxacin inhalation solution).

“Following the Raptor acquisition at the end of last year, we completed an evaluation of the commercial infrastructure required to provide PROCYSBI and QUINSAIR in Europe, the Middle East and Africa, and determined that these medicines would be best supported by a company with a larger geographic footprint,” said Timothy P Walbert, chairman, president and chief executive officer of Horizon Pharma, in a news release.

Horizon, headquartered in Dublin, Ireland, is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases.

Cooley helped take Horizon public in 2011 and has represented Horizon on nine publicly announced acquisitions and numerous credit, debt and equity financings, including its largest acquisition to date – the acquisition of Hyperion Therapeutics for $1.1 billion. In 2016, Cooley advised the company on its $800 million acquisition of Raptor Pharmaceutical. Cooley also advised on the company’s acquisition of River Vision for $145+ million in May.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.